scholarly journals Prognostic Effect of lncRNA SNHG7 On Cancer Outcome: A Meta and Bioinformatic Analysis

2021 ◽  
Author(s):  
yunyuan zhang ◽  
Qingwu Tian ◽  
Shifeng Huang ◽  
Qing Wang ◽  
Hongmei Wu ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Prognostic Value ◽  
Digestive System ◽  
Small Sample Size ◽  
Meta Analysis ◽  
Tumor Stage ◽  
Small Sample ◽  
The Cancer Genome Atlas ◽  
Significant Heterogeneity ◽  
Digestive System Cancer

Abstract Background: New evidence from clinical and fundamental researches suggests that SNHG7 is involved in the occurrence and development of carcinomas. And the increase levels of SNHG7 are associated with poor prognosis in various kinds of tumors. However, the small sample size was the limitation for the prognostic value of SNHG7 in clinical application. The aim of the present meta-analysis was to conduct a qualitative analysis to explore the prognostic value of SNHG7 in various cancers. Methods: Articles related to the SNHG7 as a prognostic biomarker for cancer patients, were comprehensive searched in several electronic databases. The enrolled articles were qualified via the preferred reporting items for systematic reviews and meta-analysis of observational studies in epidemiology checklists. Additionally, an online database based on The Cancer Genome Atlas (TCGA) was further used to validate our results.Results: We analyzed 2418 cancer patients that met the specified criteria. The present research indicated that an elevated SNHG7 expression level was significantly associated with unfavorable overall survival (OS) (HR = 2.45, 95% CI: 2.12–2.85, p <0.001). Subgroup analysis showed that high expression levels of SNHG7 were also significantly associated with unfavorable OS in digestive system cancer (HR = 2.31, 95% CI: 1.90–2.80, p <0.001) and non-digestive system cancer (HR = 2.67, 95% CI: 2.12–3.37, p <0.001). Additionally, increased SNHG7 expression was found to be associated with tumor stage and progression (III/IV vs. I/II: HR = 1.76, 95% CI: 1.57–1.98, p <0.001). Furthermore, elevated SNHG7 expression significantly predicted lymph node metastasis (LNM) (HR = 1.98, 95% CI: 1.74–2.26, p <0.001) and distant metastasis (DM) (HR = 2.49, 95% CI: 1.88–3.30, p <0.001) respectively. No significant heterogeneity was observed among these studies. SNHG7 was significantly upregulated in four cancers and the elevated expression of SNHG7 predicted shorter OS in four malignancies and worse DFS in five malignancies based on the validation using the GEPIA cohort.Conclusions: The present analysis suggests that elevated SNHG7 is significantly associated with unfavorable OS, tumor progression, LNM and DM in various carcinomas, and may be used as a promising biomarker to guide therapy for cancer patients.

scholarly journals Prognostic effect of lncRNA SNHG7 on cancer outcome: a meta and bioinformatic analysis

BMC Cancer ◽  
2022 ◽  
Vol 22 (1) ◽  
Author(s):  
Yunyuan Zhang ◽  
Qingwu Tian ◽  
Shifeng Huang ◽  
Qing Wang ◽  
Hongmei Wu ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Prognostic Value ◽  
Digestive System ◽  
Small Sample Size ◽  
Meta Analysis ◽  
Small Sample ◽  
The Cancer Genome Atlas ◽  
Significant Heterogeneity ◽  
Analysis Tool ◽  
Digestive System Cancer

Abstract Background New evidence from clinical and fundamental researches suggests that SNHG7 is involved in the occurrence and development of carcinomas. And the increased levels of SNHG7 are associated with poor prognosis in various kinds of tumors. However, the small sample size was the limitation for the prognostic value of SNHG7 in clinical application. The aim of the present meta-analysis was to conduct a qualitative analysis to explore the prognostic value of SNHG7 in various cancers. Methods Articles related to the SNHG7 as a prognostic biomarker for cancer patients, were comprehensive searched in several electronic databases. The enrolled articles were qualified via the preferred reporting items for systematic reviews and meta-analysis of observational studies in epidemiology checklists. Additionally, an online database based on The Cancer Genome Atlas (TCGA) was further used to validate our results. Results We analyzed 2418 cancer patients that met the specified criteria. The present research indicated that an elevated SNHG7 expression level was significantly associated with unfavorable overall survival (OS) (HR = 2.45, 95% CI: 2.12–2.85, p <0.001). Subgroup analysis showed that high expression levels of SNHG7 were also significantly associated with unfavorable OS in digestive system cancer (HR = 2.31, 95% CI: 1.90–2.80, p <0.001) and non-digestive system cancer (HR = 2.67, 95% CI: 2.12–3.37, p <0.001). Additionally, increased SNHG7 expression was found to be associated with tumor stage and progression (III/IV vs. I/II: HR = 1.76, 95% CI: 1.57–1.98, p <0.001). Furthermore, elevated SNHG7 expression significantly predicted lymph node metastasis (LNM) (HR = 1.98, 95% CI: 1.74–2.26, p <0.001) and distant metastasis (DM) (HR = 2.49, 95% CI: 1.88–3.30, p <0.001) respectively. No significant heterogeneity was observed among these studies. SNHG7 was significantly upregulated in four cancers and the elevated expression of SNHG7 predicted shorter OS in four cancers, worse DFS in five malignancies and worse PFI in five carcinomas based on the validation using the GEPIA on-line analysis tool. Conclusions The present analysis suggests that elevated SNHG7 is significantly associated with unfavorable OS, tumor progression, LNM and DM in various carcinomas, and may be served as a promising biomarker to guide therapy for cancer patients.

The Clinical Significance and Prognostic Value of HER2 Expression in Bladder Cancer: a Systematic Review and Meta-analysis

2020 ◽  
Author(s):  
Kai Gan ◽  
Yue Gao ◽  
KuangZheng Liu ◽  
Bin Xu ◽  
Ming Chen
Keyword(s):  
Bladder Cancer ◽  
Clinical Significance ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Growth Factor Receptor ◽  
Tumor Stage ◽  
The Cancer Genome Atlas ◽  
Her2 Expression ◽  
Large Tumor ◽  
Normal Tissues

Abstract Objective: Human Epidermal Growth Factor Receptor 2 (HER2) is highly expressed in a variety of tumors and associated with patients’ prognosis, but its role in bladder cancer remains unclear. We conducted this meta-analysis to explore the clinical significance and prognostic value of HER2 in bladder cancer and its potentiality as an immunotherapy target.Methods: PubMed was searched for studies published between January 1, 2000 and January 1, 2020. The odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (95%CIs) were used to investigate the relationship between HER2 and bladder cancer. UALCAN website was used to obtain TCGA (The cancer genome atlas) database.Results: Our study includes 14 articles, 1398 patients. HER2 expression was significantly higher in bladder cancer than in normal tissues. Our meta-analysis results did not reveal any effect of gender on the expression of HER2 levels in bladder cancer patients. However, HER2 expression in male patients was significantly higher than that in women according to TCGA databases. HER2 expression was also associated with carcinoma in situ, multifocal tumors, large tumor size, high tumor stage and grade, lymph node metastases, risk of recurrence and progression, low recurrence-free survival (RFS) rate. HER2 expression status had no effect on overall survival.Conclusions: Our meta-analysis showed that HER2 expression was related to pathological malignancy and poor prognosis in bladder cancer which indicated that it could be used as an effective biomarker and therapeutic target.

Acupuncture for the Treatment of Gastro-Oesophageal Reflux Disease: A Systematic Review and Meta-Analysis

2017 ◽  
Vol 35 (5) ◽  
pp. 316-323 ◽  
Author(s):  
Jiajie Zhu ◽  
Yu Guo ◽  
Shan Liu ◽  
Xiaolan Su ◽  
Yijie Li ◽  
...  
Keyword(s):  
Systematic Review ◽  
Reflux Disease ◽  
Small Sample Size ◽  
Meta Analysis ◽  
Small Sample ◽  
Oesophageal Reflux ◽  
Symptom Improvement ◽  
Significant Heterogeneity ◽  
Oesophageal Reflux Disease

Background Gastro-oesophageal reflux disease (GORD) is one of the most common diseases presenting to gastroenterology clinics. Acupuncture is widely used as a complementary and alternative treatment for patients with GORD. Objective To explore the effectiveness of acupuncture for the treatment of GORD. Methods Four English and four Chinese databases were searched through June 2016. Randomised controlled trials investigating the effectiveness of manual acupuncture or electroacupuncture (MA/EA) for GORD versus or as an adjunct to Western medicine (WM) were selected. Data extraction and quality evaluation were performed by two authors independently and RevMan 5.2.0 was used to analyse data. Results A total of 12 trials involving 1235 patients were included. Meta-analyses demonstrated that patients receiving MA/EA combined with WM had a superior global symptom improvement compared with those receiving WM alone (relative risk (RR) 1.17, 95% CI 1.09 to 1.26; p=0.03; six studies) with no significant heterogeneity (I2=0%, p=0.41). Recurrence rates of those receiving MA/EA alone were lower than those receiving WM (RR 0.42,95% CI 0.29 to 0.61; p<0.001; three studies) with low heterogeneity (I2=7%, p=0.34), while global symptom improvement (six studies) and symptom scores (three studies) were similar (both p>0.05). Descriptive analyses suggested that acupuncture also improves quality of life in patients with GORD. Conclusion This meta-analysis suggests that acupuncture is an effective and safe treatment for GORD. However, due to the small sample size and poor methodological quality of the included trials, further studies are required to validate our conclusions. Trial registration number PROSPERO Systematic review registration no. CRD42016041916.

scholarly journals A meta-analysis of the diagnostic accuracy of dengue virus-specific IgA antibody-based tests for detection of dengue infection

2015 ◽  
Vol 144 (4) ◽  
pp. 876-886 ◽  
Author(s):  
K. ALAGARASU ◽  
A. M. WALIMBE ◽  
S. M. JADHAV ◽  
A. R. DEOSHATWAR
Keyword(s):  
Diagnostic Accuracy ◽  
Small Sample Size ◽  
Meta Analysis ◽  
Dengue Infection ◽  
Immunoglobulin A ◽  
Diagnostic Odds Ratio ◽  
Small Sample ◽  
Significant Heterogeneity ◽  
Sample Collection ◽  
Likelihood Ratios

SUMMARYImmunoglobulin A (IgA)-based tests have been evaluated in different studies for their utility in diagnosing dengue infections. In most of the studies, the results were inconclusive because of a small sample size. Hence, a meta-analysis involving nine studies with 2096 samples was performed to assess the diagnostic accuracy of IgA-based tests in diagnosing dengue infections. The analysis was conducted using Meta-Disc software. The results revealed that IgA-based tests had an overall sensitivity, specificity, diagnostic odds ratio, and positive and negative likelihood ratios of 73·9%, 95·2%, 66·7, 22·0 and 0·25, respectively. Significant heterogeneity was observed between the studies. The type of test, infection status and day of sample collection influenced the diagnostic accuracy. The IgA-based diagnostic tests showed a greater accuracy when the samples were collected 4 days after onset of symptoms and for secondary infections. The results suggested that IgA-based tests had a moderate level of accuracy and are diagnostic of the disease. However, negative results cannot be used alone for dengue diagnosis. More prospective studies comparing the diagnostic accuracy of combinations of antigen-based tests with either IgA or IgM are needed and might be useful for suggesting the best strategy for dengue diagnosis.

scholarly journals Prognostic value of Red Blood Cell Distribution Width in Acute Kidney Injury Patients: A Systematic Review and Meta-analysis

2019 ◽  
Author(s):  
Zhengsheng Liu ◽  
Shanshan Wang ◽  
Xiongbo Yao ◽  
Jinchun Xing
Keyword(s):  
Systematic Review ◽  
Acute Kidney Injury ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Kidney Injury ◽  
Small Sample ◽  
Significant Heterogeneity ◽  
Cell Distribution ◽  
Distribution Width ◽  
Conflicting Result

AbstractBackgroundThe conflicting result with regard to Red Cell Distribution Width (RDW) with Acute Kidney Injury (AKI) has been reported. This systematic review and meta-analysis were aimed to investigate RDW and prognostic value in AKI patients.Methods/Main ResultsThis meta-analysis included 1251 cases and 1663 controls with a total of 7 enrolled published papers. The results of RDW levels were significantly associated with patients of AKI (WMD=1.127, 95% CI=0.426-1.827; P=0.002), with statistically significant heterogeneity (I2 =95.80%, Pheterogeneity =0.000, random-effects model).ConclusionsIn conclusion, the results of this present meta-analysis suggest that the RDW value is a positive prognostic indicator in patients with AKI. However, these results were obtained on the basis of RCS or small sample sizes studies. Further functional studies with additional data would be needed to validate our findings.

scholarly journals The prognostic value of METTL3 in cancer patients: a meta-analysis

2020 ◽  
Author(s):  
Xingzhu Pan ◽  
Haolin Li ◽  
Yuyuan Xu ◽  
Chengcheng He ◽  
Qiuhua Lai ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Prognostic Value ◽  
Digestive System ◽  
Meta Analysis ◽  
Disease Free Survival ◽  
High Expression ◽  
Literature Information ◽  
Free Survival ◽  
Cancer Types ◽  
Disease Free

Abstract Background: M6A methylation modification of RNA can regulate the development of tumor cells. METTL3 is one of the modified methyltransferases. A growing number of studies have shown that high expression of METTL3 may be associated with the unfavorable prognosis in cancer patients and may become a new biomarker. Therefore, this meta-analysis was used to evaluate the prognostic value of METTL3 in cancer patients through the available literature information.Methods: Relevant studies were retrieved from electronic literature databases including six English databases and three Chinese databases. Correlation analysis was conducted by Stata SE 15.1 and RevMan 5.3 software. We analyzed 11 eligible studies with a total of 1638 cancer patients in this meta-analysis. We took advantage of HRs and ORs with 95% confidence intervals to evaluate the prognostic value of METTL3 in tumors. Besides,the article was qualified by MOOSE check lists and PRISMA Checklist. Results: The results of the meta-analysis indicated that high expression of METTL3 was associated with low overall survival (OS) (HR=2.67, 95%CI:2.19-3.25, P<0.00001) and disease-free survival (DFS) (HR=2.23, 95%CI:1.60-3.11, P<0.00001) in various cancers.Stratified analysis of cancer types showed that over expressed METTL3 was related to poor prognosis in digestive system cancer patients, including CRC(HR=2.29, 95%CI:1.50-3.49，P=0.0001) ,GC(HR=2.96，95%CI:2.13-4.12，P＜0.00001)，and liver cancer（HR=2.70，95%CI:1.88-3.88，P＜0.00001). Meanwhile, the elevated METTL3 expression also affected the lymph node metastasis (OR=3.40，95%CI=1.58-7.33，p=0.002) ，vascular invasion (OR=2.04，95%CI=1.06-3.95，p=0.03) and the tumors progression (III/IV vs. I/II: OR = 3.72, 95% CI: 1.94 - 7.13, P < 0.0001).Conclusion: The existing analysis indicates that METTL3 is associated with low OS and DFS in cancer patients and may serve as a biomarker to assess prognostic value.

scholarly journals The influence of gender and ethnicity on facemasks and respiratory protective equipment fit: a systematic review and meta-analysis

2021 ◽  
Vol 6 (11) ◽  
pp. e005537
Author(s):  
Jagrati Chopra ◽  
Nkemjika Abiakam ◽  
Hansung Kim ◽  
Cheryl Metcalf ◽  
Peter Worsley ◽  
...  
Keyword(s):  
Small Sample Size ◽  
Meta Analysis ◽  
A Priori ◽  
White Male ◽  
Small Sample ◽  
Protective Equipment ◽  
Significant Heterogeneity ◽  
Anthropometric Data ◽  
Male Population ◽  
Gender Based

IntroductionBlack, Asian and minority ethnic (BAME) people are disproportionately affected by COVID-19. Respiratory protective equipment (RPE) has conventionally been developed for a predominantly white male population that does not represent the healthcare workforce. The literature was reviewed to determine the protection offered to female and BAME users.MethodsFive databases were searched. Eligible studies related to respirator fit in the context of anthropometrics, gender and ethnicity. Meta-analysis was performed for gender-based anthropometric differences. A priori protocol registration was not performed.Results32 studies were included and anthropometric data was extracted from 15 studies. Meta-analysis revealed 14 anthropometric measurements were significantly smaller for females. Mean differences ranged from 0.37 mm to 22.05 mm. Gender-based anthropometric differences did not always translate to lower fit factor scores, with 12 studies reporting worse performance and fit for females and 10 reporting no gender effect. No studies provided disaggregate anthropometric data by ethnic group. Pass rates (PR) were low or moderate in 12 BAME or mixed-ethnicity cohorts. 14 studies reported associations between facial dimensions (FD) and respirator fit. Three comparative studies showed lower PR among selective BAME people. 18 studies reported RPE performance differed with model and design. Most studies did not prespecify inclusion/exclusion criteria. Small sample size and lack of justification or power calculations was a concern. Significant heterogeneity in study designs limited comparisons, particularly relating to respirator selection or availability and defining study outcomes relating to RPE performance.ConclusionThe literature reports on largely Caucasian or single ethnic populations, and BAME people remain under-represented, limiting comparisons between ethnic groups. Facial anthropometrics vary between gender and likely between ethnicity, which may contribute to lower PR among females and ethnic minorities, particularly Asians. There is a need for studies including a broader spectrum of ethnicities and for consideration of female and BAME users during RPE development.

scholarly journals Prognostic significance of microRNA-135 in patients with digestive system cancers: a systematic review and meta-analysis

2019 ◽  
Vol 39 (12) ◽  
Author(s):  
Ce Chao ◽  
Chen Sang ◽  
Min Wang ◽  
Zijin Wang ◽  
Yanfei Li ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Large Scale ◽  
Digestive System ◽  
Meta Analysis ◽  
Prognostic Significance ◽  
Disease Free Survival ◽  
The Cancer Genome Atlas ◽  
Cochrane Library ◽  
Free Survival ◽  
Non Coding Rna

Abstract Background: MicroRNA-135 (miR-135) is a well-known non-coding RNA that has been demonstrated to participate in tumorigenesis and cancer development; however, the clinical prognostic value of miR-135 in digestive system cancers remains controversial. This meta-analysis aims to explore the potential value of miR-135 as a prognostic marker for digestive system cancers. Methods: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible articles published before 31 August 2019. Stata 12.0 software was used to analyze the overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) rates to access the prognostic value of miR-135 in digestive system cancers. We then used The Cancer Genome Atlas (TCGA) datasets to validate the meta-analysis results. Results A total of 1470 patients from 17 studies were included in this meta-analysis. The pooled results showed that enhanced miR-135 expression was significantly associated with poor OR (hazard ratio (HR): 1.790; 95% confidence interval (95% CI): 1.577–2.031; P=0.000), DFS (HR: 1.482; 95% CI: 0.914–2.403; P=0.110), and RFS (HR: 3.994; 95% CI: 1.363–11.697; P=0.012) in digestive system cancers. A sensitivity analysis confirmed the reliability of our findings, and no significant publication bias was observed. Conclusion: MiR-135 can be used as a novel biomarker for patients with digestive system cancers. We look forward to future large-scale clinical studies that will investigate the prognostic value of miR-135.

scholarly journals The incidence and prevalence of cardiovascular diseases in gout: a systematic review and meta-analysis

2021 ◽  
Author(s):  
Peter Cox ◽  
Sonal Gupta ◽  
Sizheng Steven Zhao ◽  
David M. Hughes
Keyword(s):  
Systematic Review ◽  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Cardiovascular Diseases ◽  
Small Sample Size ◽  
Meta Analysis ◽  
Random Effect ◽  
Small Sample ◽  
Future Research ◽  
Increased Risk

AbstractThe aims of this systematic review and meta-analysis were to describe prevalence of cardiovascular disease in gout, compare these results with non-gout controls and consider whether there were differences according to geography. PubMed, Scopus and Web of Science were systematically searched for studies reporting prevalence of any cardiovascular disease in a gout population. Studies with non-representative sampling, where a cohort had been used in another study, small sample size (< 100) and where gout could not be distinguished from other rheumatic conditions were excluded, as were reviews, editorials and comments. Where possible meta-analysis was performed using random-effect models. Twenty-six studies comprising 949,773 gout patients were included in the review. Pooled prevalence estimates were calculated for five cardiovascular diseases: myocardial infarction (2.8%; 95% confidence interval (CI)s 1.6, 5.0), heart failure (8.7%; 95% CI 2.9, 23.8), venous thromboembolism (2.1%; 95% CI 1.2, 3.4), cerebrovascular accident (4.3%; 95% CI 1.8, 9.7) and hypertension (63.9%; 95% CI 24.5, 90.6). Sixteen studies reported comparisons with non-gout controls, illustrating an increased risk in the gout group across all cardiovascular diseases. There were no identifiable reliable patterns when analysing the results by country. Cardiovascular diseases are more prevalent in patients with gout and should prompt vigilance from clinicians to the need to assess and stratify cardiovascular risk. Future research is needed to investigate the link between gout, hyperuricaemia and increased cardiovascular risk and also to establish a more thorough picture of prevalence for less common cardiovascular diseases.

Sign in / Sign up

Export Citation Format

Share Document